Report overview
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
This report contains market size and forecasts of Solid Tumors Drugs in global, including the following market information:
Global Solid Tumors Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Solid Tumors Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Solid Tumors Drugs companies in 2021 (%)
The global Solid Tumors Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Small Molecules Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Solid Tumors Drugs include Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, BMS, Eli Lilly, GSK and Merck, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Solid Tumors Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Solid Tumors Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Solid Tumors Drugs Market Segment Percentages, by Type, 2021 (%)
Small Molecules
Biologics
Global Solid Tumors Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Solid Tumors Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Academic and Research Institutes
Others
Global Solid Tumors Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Solid Tumors Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Solid Tumors Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Solid Tumors Drugs revenues share in global market, 2021 (%)
Key companies Solid Tumors Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Solid Tumors Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
Eli Lilly
GSK
Merck
Sanofi
AbbVie
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim
Boston Biomedical
Daiichi Sankyo
